Past Issues: Endocrine disease

June 2009

Distillery: Therapeutics

Diabetes

AMP-activated protein kinase (AMPK)

Published online June 25 2009; doi:10.1038/scibx.2009.1009

A sulfonamide prodrug of generic metformin could be useful for reducing the daily dosage of the drug and decreasing gastrointestinal side effects in type 2 diabetes patients.

Summary | PDF (111 KB)

Distillery: Therapeutics

Diabetes

Sirtuin 1 (SIRT1)

Published online June 25 2009; doi:10.1038/scibx.2009.1010

Studies in rats suggest that inhibiting hepatic SIRT1 could help treat type 2 diabetes.

Summary | PDF (112 KB)

Distillery: Therapeutics

Diabetes; obesity

Leptin receptor (LEPR)

Published online June 25 2009; doi:10.1038/scibx.2009.1011

Studies in mice suggest that boosting LEPR activity on proopiomelanocortin (POMC) neurons could help prevent diabetes and obesity.

Summary | PDF (111 KB)

Distillery: Therapeutics

Calcium channel voltage-dependent T-type alpha1G subunit (CACNA1G; Cav3.1)

Published online June 11 2009; doi:10.1038/scibx.2009.941

Studies in rodents suggest that antagonizing the T-type calcium channel CACNA1G could help treat obesity and metabolic syndrome.

Summary | PDF (115 KB)

Distillery: Therapeutics

IL-10; IL-19; IL-20; IL-27; GLIS family zinc finger 3(GLIS3); CD69

Published online June 4 2009; doi:10.1038/scibx.2009.910

A genomewide association study and meta-analysis identified genetic variants that could help assess the risk of type 1 diabetes.

Summary | PDF (112 KB)

Distillery: Therapeutics

Histamine H3 receptor (HRH3)

Published online June 4 2009; doi:10.1038/scibx.2009.911

An SAR study characterized a series of HRH3 inverse agonists that could help treat obesity.

Summary | PDF (109 KB)